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Will the revolution in genetics improve healthcare?
We need randomised trials to tell us
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The newmillennium has brought with it an explosion in genetic
knowledge. Future generations are likely to look back at this
time as the beginning of a new era in human genetics and health.
The major challenge facing researchers is how to translate this
new knowledge into improved health and healthcare, and
progress has been slower than predicted.1 2 Simply knowing that
a genetic variant is associated with an increased risk of a disease
or that it influences a response to drug treatment is only half
the picture. The new research frontiers are how this knowledge
should be used and assessing the clinical and cost effectiveness
of such use. A linked research study by Hollands and colleagues
(doi:10.1136/bmj.e4708) is a pioneering attempt to use a genetic
discovery to improve healthcare.3
Increased knowledge of the underlying genetic causes of disease
has alreadymademajor contributions. For example, the finding
that genetic variants of components of the complement pathway
were associated with age related macular degeneration
stimulated a whole new area of research and suggested possible
drug targets for what had been a largely untreatable disease.4
Improvement in knowledge is sufficient justification for this
kind of genetic research. Immediate health gain is not the aim:
the hope is for translation into improved health at some time in
the future.
However, for two other major areas of genetic
research—prediction of disease risk and
pharmacogenetics—improvements in health may be more
immediate. In the past decade genetic variants that influence a
range of commonmultifactorial disorders or that affect response
to drug treatment have been identified reliably. However, current
knowledge explains only a small proportion of the heritability
of most diseases.5 The genetic basis for many adverse drug
reactions is unknown, with even less known about genetic
factors associated with poor response to treatment.6 Continued
research aimed at understanding how genes influence human
health is clearly needed.
Hollands and colleagues’ study was based on the association
between the NOD2 gene (which encodes nucleotide binding
oligomerisation domain containing protein 2) and Crohn’s
disease. First degree relatives of people with Crohn’s disease
have a higher risk of the disease compared with the general
population. This increased risk is enhanced by the presence of
NOD2 mutations, with greater risk being conferred by two
mutations than by one. Smoking is an established causal risk
factor for Crohn’s disease, and quitting decreases the risk of the
disease. The main hypothesis tested in the study was that
informing people of their genetic risk of Crohn’s disease on the
basis of their NOD2 genotype would motivate them to stop
smoking. Crucially, the authors not only implemented the use
of genetic knowledge but they evaluated the effectiveness of
using the knowledge in a randomised trial. The comparison
group was offered non-DNA based risk information. All
participants were smokers who had first degree relatives with
Crohn’s disease and thus all had a high risk of the disease.
Although the study was negative—smoking quit rates did not
differ between the two arms—the authors are to be applauded
for undertaking a rigorous randomised trial in an area where
strong evidence is lacking. However, their conclusion that
genetic knowledge of disease risk does not motivate behaviour
change may be too sweeping given aspects of the study that
could have contributed to the negative result. People’s genetic
risk was communicated by post in the form of a booklet.
Although a smoking cessation counsellor made a follow-up call,
face to face communication of risk may have been more
effective. Only 50 of 209 people (24%) in the intervention group
had one or more NOD2 mutations, so any impact would have
been restricted to these 50 people, which compromised the
statistical power of the study to detect a beneficial effect. But,
perhaps most importantly, the increased risk of Crohn’s disease
conferred byNOD2 variants (ranging from double to sevenfold)
is dwarfed by the massively increased risk (20-fold) in all
participants through them having a first degree relative with the
disease. The incremental effect of knowing NOD2 status might
thus be expected to be small.
In spite of these limitations, Hollands and colleagues’ study is
a welcome and important addition to the literature because it
used the most reliable and robust tool to assess effectiveness:
the randomised trial. Knowledge of genetics will continue to
increase rapidly, particularly as the use of whole genome
sequencing becomes more widespread. Improved prediction of
risk and better targeting of drugs are realistic expectations.
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However, new technologies and models of care that are based
on genetic information need to be rigorously evaluated before
they are implemented. The optimal test will be a randomised
trial comparing care that does and does not use genetic
knowledge. Typically trials will test interventions tailored to
individuals according to a composite of their personal genetic
information along with other clinical factors. Such trials are
needed to tell us which aspects of healthcare can be improved
by the revolution in genetics.
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